Seller record · Telehealth service

Bon Health

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 3 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The home page and answers refer only to US-licensed 503A and 503B compounding pharmacies, and the terms to independently owned pharmacies. 2 more criteria also fail; see the table below.

At a glance

Bon HealthTelehealth service

5/8criteria passed

Price: Semaglutide $220 a month billed monthly, from $95 a month on the annual plan; tirzepatide $285, from $135
Sells: compounded semaglutide, compounded tirzepatide, Wegovy, and 3 more
FDA letters: None on file

Visit Bon Health See all eight dispositions

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A telehealth company selling compounded semaglutide and tirzepatide on monthly to annual plans, and brand-name Wegovy, Ozempic, Zepbound and Mounjaro at list prices, with care from independent medical groups. Care starts with a short online questionnaire, and no pharmacy is named.

Operating entity Bon Health Corporation

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Bon Health's website; Bon Health's terms
S2	Prescription gating	PASS	Bon Health's website; Bon Health's compounded semaglutide product page; Bon Health's how it works page
S3	Pharmacy identification	FAIL	Bon Health's website; Bon Health's terms
S4	Compounding disclosure	PASS	Bon Health's website; Bon Health's compounded semaglutide product page
S5	Analytical documentation	FAIL	Bon Health's compounded semaglutide product page; Bon Health's terms; Bon Health's medical disclaimer page
S6	Business address	FAIL	Bon Health's terms; Bon Health's privacy page; Bon Health's medical disclaimer page
S7	Price disclosure	PASS	Bon Health's compounded semaglutide product page; Bon Health's compounded tirzepatide product page; Bon Health's website
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSThe home page says medication is dispensed only after an online consultation with a licensed provider who decides whether a prescription is clinically appropriate, and the answers say every prescription is written by a US-licensed physician. The footer says care is provided by independent medical groups.Source: Bon Health's website; Bon Health's terms.

S2PASSThe home page says a buyer first fills out a short questionnaire that a clinician reviews the same day, and that medication is dispensed only after that consultation; the product pages say the price is confirmed at checkout. No page describes a payment step before the questionnaire.Source: Bon Health's website; Bon Health's compounded semaglutide product page; Bon Health's how it works page.

S3FAILNo filling pharmacy is named. The home page and answers refer only to US-licensed 503A and 503B compounding pharmacies, and the terms to independently owned pharmacies.Source: Bon Health's website; Bon Health's terms.

S4PASSThe home page, the product pages and the footer state that compounded semaglutide and tirzepatide are not FDA-approved and that the FDA does not evaluate compounded medications for safety, effectiveness or quality.Source: Bon Health's website; Bon Health's compounded semaglutide product page.

S5FAILNo certificate of analysis or lot document is published on the home page, the product pages, the terms or the medical disclaimer.Source: Bon Health's compounded semaglutide product page; Bon Health's terms; Bon Health's medical disclaimer page.

S6FAILThe terms, the privacy policy and the medical disclaimer name Bon Health Corporation, a Delaware corporation, but every contact and notice block gives only an email address; no postal address is printed.Source: Bon Health's terms; Bon Health's privacy page; Bon Health's medical disclaimer page.

S7PASSCompounded semaglutide at $220 billed monthly, $420 every 3 months, $690 every 6 months or $1,140 a year, which the page works out to $140, $115 and $95 a month; its heading prints $140 a month beside an original price of $220. Compounded tirzepatide at $285 monthly, $615, $1,110 or $1,620, or $205, $185 and $135 a month, with $205 beside an original price of $285. The home page says there is no membership fee, while its answers describe a membership at $30 for the first month and then $70 a month, $150 a quarter or $749 a year. Brand-name Wegovy at $1,869 a month, Ozempic at $1,319, Zepbound at $1,469 and Mounjaro at $1,269.Source: Bon Health's compounded semaglutide product page; Bon Health's compounded tirzepatide product page; Bon Health's website.

S8PASSNo FDA warning letter names Bon Health or Bon Health Corporation, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, Wegovy, Ozempic, Zepbound, Mounjaro.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit Bon Health

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.